AU8950291A - Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging - Google Patents

Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging

Info

Publication number
AU8950291A
AU8950291A AU89502/91A AU8950291A AU8950291A AU 8950291 A AU8950291 A AU 8950291A AU 89502/91 A AU89502/91 A AU 89502/91A AU 8950291 A AU8950291 A AU 8950291A AU 8950291 A AU8950291 A AU 8950291A
Authority
AU
Australia
Prior art keywords
deferoxamine
polymer
magnetic resonance
resonance imaging
ferric iron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU89502/91A
Inventor
Phillip E Hallaway
Bo E Hedlund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomedical Frontiers Inc
Original Assignee
Biomedical Frontiers Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedical Frontiers Inc filed Critical Biomedical Frontiers Inc
Publication of AU8950291A publication Critical patent/AU8950291A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU89502/91A 1990-10-16 1991-10-15 Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging Abandoned AU8950291A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59804490A 1990-10-16 1990-10-16
US598044 1990-10-16

Publications (1)

Publication Number Publication Date
AU8950291A true AU8950291A (en) 1992-05-20

Family

ID=24393999

Family Applications (1)

Application Number Title Priority Date Filing Date
AU89502/91A Abandoned AU8950291A (en) 1990-10-16 1991-10-15 Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging

Country Status (5)

Country Link
EP (1) EP0553273A4 (en)
JP (1) JPH06502177A (en)
AU (1) AU8950291A (en)
CA (1) CA2094028A1 (en)
WO (1) WO1992007259A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU673153B2 (en) * 1992-01-15 1996-10-31 University Of Washington A method for estimating the biologic potential of a selected carcinoma in a patient

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707604A (en) * 1986-11-18 1998-01-13 Access Pharmaceuticals, Inc. Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5494030A (en) * 1993-08-12 1996-02-27 Trustees Of Dartmouth College Apparatus and methodology for determining oxygen in biological systems
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
AT409929B (en) * 1997-03-07 2002-12-27 Tritthart Helmut A Dr Infusion solution containing inert macromolecule becoming preferentially enriched in tumor-associated neovascularization regions, useful as carrier and targeting agent in tumor diagnosis and therapy
DE19808079A1 (en) * 1998-02-20 1999-08-26 Schering Ag New hydroxyethyl starch conjugates useful as X-ray, NMR and blood-pool diagnostic agents, e.g. for diagnosis of tumors, cardiovascular disorders and inflammation
IL127621A (en) * 1998-12-17 2002-05-23 Yissum Res Dev Co Method for measuring non-bound metal in serum and biological fluids
EP1404334A4 (en) * 2001-05-15 2005-02-02 Faulk Pharmaceuticals Inc Targeted delivery of bioaffecting compounds for the treatment of cancer
US6961607B2 (en) 2002-07-31 2005-11-01 Uzgiris Egidijus E Method for assessing myocardial angiogenesis
US20040024317A1 (en) * 2002-07-31 2004-02-05 Uzgiris Egidijus E. Method for assessing capillary permeability
KR20110079741A (en) * 2002-12-09 2011-07-07 아브락시스 바이오사이언스, 엘엘씨 Compositions and methods of delivery of pharmacological agents
AU2003299590B8 (en) 2002-12-09 2010-04-08 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
CN114460163B (en) * 2022-02-11 2023-03-03 河北师范大学 MALDI mass spectrometry imaging method for detecting iron content of biological tissue

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56125317A (en) * 1980-03-08 1981-10-01 Nippon Mejifuijitsukusu Kk Stable radioactive diagnosticum with radioactive metallic mark
US4666697A (en) * 1982-12-08 1987-05-19 Nihon Medi-Physics Co., Ltd. Radioactive diagnostic agent
US4863964A (en) * 1985-07-02 1989-09-05 Biomedical Frontiers, Inc. Method for the stabilization of deferoxamine to chelate free ions in physiological fluid
GB8610551D0 (en) * 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
US4999445A (en) * 1988-06-10 1991-03-12 The Regents Of The University Of California Contrast agents for magnetic resonance imaging of the small intestine and hepatobiliary system

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU673153B2 (en) * 1992-01-15 1996-10-31 University Of Washington A method for estimating the biologic potential of a selected carcinoma in a patient

Also Published As

Publication number Publication date
JPH06502177A (en) 1994-03-10
EP0553273A4 (en) 1998-04-22
WO1992007259A1 (en) 1992-04-30
CA2094028A1 (en) 1992-04-17
EP0553273A1 (en) 1993-08-04

Similar Documents

Publication Publication Date Title
EP0465068A3 (en) Switched field magnetic resonance imaging
EP0412695A3 (en) Magnetic resonance imaging
AU3359889A (en) Contrast agents for magnetic resonance imaging
EP0412824A3 (en) Magnetic resonance imaging system
GB2275538B (en) Frustoconical magnet for magnetic resonance imaging
EP0443677A3 (en) Quadrature surface coil construction for magnetic resonance imaging apparatus
GB2245364B (en) Magnetic resonance imaging coil
AU8950291A (en) Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging
EP0450949A3 (en) Actively shielded magnetic resonance magnet without cryogens
GB8813425D0 (en) Magnetic resonance imaging
EP0495287A3 (en) Magnetic resonance imaging
GB2240628B (en) Magnetic resonance imaging apparatus
SG49633A1 (en) Magnetic resonance imaging apparatus
EP0453102A3 (en) Magnetic resonance imaging methods and apparatus
IL97712A0 (en) Super conducting magnet
GB2234594B (en) Nuclear magnetic resonance imaging methods
IL85785A0 (en) Quadrature magnetic arrangement surface coil for resonance spectroscopy or imaging system
EP0430104A3 (en) Magnetic resonance imaging apparatus
EP0439119A3 (en) Magnetic resonance imaging system
GB9007655D0 (en) Magnetic resonance imaging technique
GB9017816D0 (en) Magnetic resonance imaging sequencer gating
IL98977A0 (en) Echo-volumar magnetic resonance imaging using 180grad rf pulses
AU7044791A (en) Transition metal complexes for magnetic resonance diagnosis
GB2234595B (en) Nuclear magnetic resonance imaging methods
AU6280794A (en) High relaxivity, paramagnetic, metal complexes for magnetic resonance imaging